Related Experiment Video
Updated: May 3, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung
Xiao-Yan Mu1, Xue-Li Dong, Jie Sun
1Provincial Hospital Affiliated to Shandong University, Eastern Hospital Care in Department of Respiration, Jinan, China
Abstract:
The effects of erlotinib combined with celecoxib in a lung cancer xenograft model were here explored with a focus on possible mechanisms. A xenotransplanted lung cancer model was established in nude mice using the human lung cancer cell A549 cell line and animals demonstrating tumour growth were randomly divided into four groups: control, erlotinib, celecoxib and combined (erotinib and celecoxib). The tumor major axis and short diameter were measured twice a week and after 40 days tissues were collected for immunohistochemical analyses of Bcl-2 and Bax positive cells and Western-blotting analyses for the epidermal growth factor recepto (EGFR), P-EGFR, and cyclooxygenase-2 (COX-2). Tumor size in the combined group was smaller than in the others (p<0.01) and the percentage of Bcl-2 positive cells was fewer in most cases (p<0.01), while that of Bax positive cells was greater than in the erlotinib and celecoxib groups (P>0.05). Western blotting showed decreased expression of P-EGFR and COX-2 with both erlotinib and celecoxib treatments, but most pronouncedly in the combined group (P<0.05). Simultaneous blockage of the EGFR and COX-2 signal pathways exerted stronger growth effects in our human xenotransplanted lung cancer model than inhibition of either pathway alone. The anti-tumor effects were accompanied by synergetic inhibition of tumor cell apoptosis, activation of p-EGFR and expression of COX-2.
Insights
Combining erlotinib and celecoxib significantly inhibited lung cancer xenograft growth. This combination therapy demonstrated enhanced anti-tumor effects by simultaneously blocking EGFR and COX-2 pathways, leading to increased apoptosis.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Lung cancer remains a leading cause of cancer-related mortality worldwide.
- Targeted therapies like erlotinib (EGFR inhibitor) and celecoxib (COX-2 inhibitor) show promise but can be limited by resistance mechanisms.
- Investigating combination therapies is crucial for overcoming treatment resistance and improving patient outcomes.
Purpose of the Study:
- To evaluate the synergistic anti-tumor effects of combining erlotinib and celecoxib in a human lung cancer xenograft model.
- To elucidate the underlying molecular mechanisms responsible for the enhanced therapeutic efficacy.
Main Methods:
- A549 human lung cancer cell line xenograft model established in nude mice.
- Mice were randomized into four groups: control, erlotinib, celecoxib, and combination therapy.
- Tumor growth was monitored, and tissues were analyzed via immunohistochemistry and Western blotting for key proteins (Bcl-2, Bax, EGFR, P-EGFR, COX-2).
Main Results:
- Combined erlotinib and celecoxib treatment resulted in significantly smaller tumor size compared to monotherapy groups (p<0.01).
- The combination therapy led to decreased Bcl-2 positive cells and increased Bax positive cells, indicating enhanced apoptosis.
- Western blotting revealed pronounced downregulation of P-EGFR and COX-2 expression in the combination group (P<0.05).
Conclusions:
- Simultaneous blockade of EGFR and COX-2 signaling pathways exerts superior anti-lung cancer growth effects compared to inhibiting either pathway alone.
- The combination therapy demonstrates synergistic anti-tumor activity, associated with enhanced apoptosis and modulation of key signaling proteins.
- This study supports the potential of combining erlotinib and celecoxib as an effective strategy for lung cancer treatment.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
